Immorna Biotherapeutics today announced the successful dosing of the first patient in its clinical study of JCXH-213, an innovative in vivo Chimeric Antigen Receptor (CAR) therapy. This milestone represents the world’s first human application of a messenger RNA (mRNA)-lipid nanoparticle (LNP)-based in vivo CAR therapy.

JCXH-213 utilizes Immorna’s advanced mRNA platform and proprietary targeted Lipid Complex Nano Particles (tLCNP) delivery system. Unlike conventional CAR-T therapies that require ex vivo collection, expansion, and genetic modification of patient or donor cells, JCXH-213 directly delivers CAR-encoding mRNA to various immune cells (including T cells, NK cells, and macrophages) in vivo. These cells then assemble the CAR complex internally, equipping them with potent anti-tumor capabilities.

If proven successful in clinical trials, JCXH-213 could address critical limitations associated with current ex vivo CAR-T therapies, such as complex manufacturing processes, high treatment costs, and lengthy patient wait times. Moreover, the mRNA approach mitigates the risk of genomic integration, thereby significantly reducing the potential for secondary malignancies.

Looking ahead, the in vivo CAR technology has the potential to not only transform cancer immunotherapy but also extend its application to autoimmune diseases, offering new hope to patients worldwide.

Immorna extends its gratitude to Beijing GoBroad Hospital for their strong support in this groundbreaking study. This collaboration underscores the company’s commitment to partnering with leading clinical institutions to rapidly advance and refine this cutting-edge technology.